Immune System Diseases

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

InmunotekSpain - Madrid

2 programs

10 HEP/mL Betula verrucosa allergen extractPhase 21 trial

Allergen extractsN/A1 trial

Active Trials

NCT02527122Completed30Est. Aug 2018

NCT02527187Completed201Est. Nov 2016

BiocorpFrance - Issoire

1 program

HIB210Phase 1

BiogenCAMBRIDGE, MA

2 programs

CDP7657PHASE_11 trial

HIB210PHASE_11 trial

Active Trials

NCT01764594Completed24Est. Aug 2014

NCT05928585Completed30Est. Jun 2024

UCB PharmaBelgium - Brussels

2 programs

CDP7657PHASE_11 trial

CDP7657PHASE_1

Active Trials

NCT01093911Completed44Est. Dec 2012

Allergy TherapeuticsUK - West Sussex

1 program

Activation and Function of Eosinophils in Conditions With Blood or Tissue EosinophiliaN/A1 trial

Active Trials

NCT00001406Recruiting800

Human BioSciencesWV - Martinsburg

1 program

Developing Newborn Screening for Infants With Primary ImmunodeficiencyN/A1 trial

Active Trials

NCT00113464Completed100Est. Apr 2007

Genome & CompanyKorea - Suwon

1 program

Developing Newborn Screening for Infants With Primary ImmunodeficiencyN/A

Sharp TherapeuticsPA - Pittsburgh

1 program

ZostavaxN/A

Merck & Co.RAHWAY, NJ

1 program

ZostavaxN/A1 trial

Active Trials

NCT01328548Completed241Est. Mar 2015

MSDIreland - Ballydine

1 program

ZostavaxN/A

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Inmunotek10 HEP/mL Betula verrucosa allergen extract

BiogenHIB210

BiogenCDP7657

UCB PharmaCDP7657

InmunotekAllergen extracts

Merck & Co.Zostavax

Human BioSciencesDeveloping Newborn Screening for Infants With Primary Immunodeficiency

Allergy TherapeuticsActivation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Clinical Trials (8)

Total enrollment: 1,470 patients across 8 trials

NCT02527187 Inmunotek10 HEP/mL Betula verrucosa allergen extract

Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa

Start: Sep 2015Est. completion: Nov 2016201 patients

Phase 2Completed

NCT05928585 BiogenHIB210

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

Start: Jul 2023Est. completion: Jun 202430 patients

Phase 1Completed

NCT01764594 BiogenCDP7657

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Start: Jan 2013Est. completion: Aug 201424 patients

Phase 1Completed

NCT01093911 UCB PharmaCDP7657

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Start: Mar 2010Est. completion: Dec 201244 patients

Phase 1Completed

NCT02527122 InmunotekAllergen extracts

Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts

Start: Jul 2016Est. completion: Aug 201830 patients

N/ACompleted

NCT01328548 Merck & Co.Zostavax

Zoster Vaccine Response in the Frail Elderly

Start: May 2011Est. completion: Mar 2015241 patients

N/ACompleted

NCT00113464 Human BioSciencesDeveloping Newborn Screening for Infants With Primary Immunodeficiency

Developing Newborn Screening for Infants With Primary Immunodeficiency

Start: Jun 2005Est. completion: Apr 2007100 patients

N/ACompleted

NCT00001406 Allergy TherapeuticsActivation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Start: Apr 1997800 patients

N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,470 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.